S2CID 20228358
doi: 10.2337/db05-1145 Summary Keywords GLP-1RA, tumor diseases, function, mechanism, agonists Citation Ji L, He X, Min X, Yang H, Wu W, Xu H, Chen J and Mei A (2024) Glucagon-like peptide-1 receptor agonists in neoplastic diseases
Rybelsus is an FDA-approved oral Semaglutide for managing type 2 diabetes, not weight loss
You may also experience vomiting with continued use of the drug, which can cause acid reflux and irritate your digestive system

drug should appear clear and colorless Do not use semaglutide if particulate matter and coloration observed Instructions for Wegovy SC Injection (Video) Side Effects Very Common: may affect more than 1 in 10 people feeling or being sick (nausea or vomiting) diarrhea constipation stomach pain feeling weak or tired headache these usually goes away over time Common: may affect up to 1 in 10 people feeling dizzy upset stomach or indigestion burping gas (flatulence) bloating of the stomach inflamed stomach (gastritis) the signs include stomach-ache, feeling sick (nausea) or being sick (vomiting) reflux or heartburn also called gastro-esophageal reflux disease hair loss injection site reactions low blood sugar (hypoglycaemia) in patients with diabetes low blood pressure increase of pancreatic enzymes (such as lipase) shown in blood tests hemorrhoids upset stomach or indigestion burping gas (flatulence) bloating of the stomach inflamed stomach (gastritis) the signs include stomach-ache, feeling sick (nausea) or being sick (vomiting) reflux or heartburn also called gastro-esophageal reflux disease hair loss injection site reactions low blood sugar (hypoglycaemia) in patients with diabetes low blood pressure increase of pancreatic enzymes (such as lipase) shown in blood tests hemorrhoids Uncommon: may affect up to 1 in 100 people fast heartbeat increase of pancreatic enzymes (such as amylase) shown in blood tests feeling faint or fainting/passing out low blood sugar (hypoglycaemia) in patients without diabetes Children and Adolescents Not recommended in children and adolescents under 18 years of age as the safety and efficacy in this age group have not yet been studied
/https%3A%2F%2Fopengraph.b-cdn.net%2Fproduction%2Fimages%2F2ed46913-f157-43c3-9418-19fea49af16c.png%3Ftoken%3DUl4O1QAtXTaMUjOfpBooUL-C8jajM-YwYFPrjCtr6ms%26height%3D1080%26width%3D1080%26expires%3D33315971423/og.png)
[3] If constipation persists despite appropriate laxative use, or if symptoms worsen, medical review is warranted to exclude other contributing factors or complications